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BACKGROUND AND PURPOSE
The effects of ketamine in attenuating morphine tolerance have been suggested to result from a pharmacodynamic
interaction. We studied whether ketamine might increase brain morphine concentrations in acute coadministration, in
morphine tolerance and morphine withdrawal.
EXPERIMENTAL APPROACH
Morphine minipumps (6 mg·day–1) induced tolerance during 5 days in Sprague–Dawley rats, after which s.c. ketamine
(10 mg·kg–1) was administered. Tail flick, hot plate and rotarod tests were used for behavioural testing. Serum levels and
whole tissue brain and liver concentrations of morphine, morphine-3-glucuronide, ketamine and norketamine were measured
using HPLC-tandem mass spectrometry.
KEY RESULTS
In morphine-naïve rats, ketamine caused no antinociception whereas in morphine-tolerant rats there was significant
antinociception (57% maximum possible effect in the tail flick test 90 min after administration) lasting up to 150 min. In the
brain of morphine-tolerant ketamine-treated rats, the morphine, ketamine and norketamine concentrations were 2.1-, 1.4-
and 3.4-fold, respectively, compared with the rats treated with morphine or ketamine only. In the liver of morphine-tolerant
ketamine-treated rats, ketamine concentration was sixfold compared with morphine-naïve rats. After a 2 day morphine
withdrawal period, smaller but parallel concentration changes were observed. In acute coadministration, ketamine increased
the brain morphine concentration by 20%, but no increase in ketamine concentrations or increased antinociception was
observed.
CONCLUSIONS AND IMPLICATIONS
The ability of ketamine to induce antinociception in rats made tolerant to morphine may also be due to increased brain
concentrations of morphine, ketamine and norketamine. The relevance of these findings needs to be assessed in humans.
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Introduction
The treatment of neuropathic pain and severe cancer pain
remains a major challenge. Opioids such as morphine and
oxycodone are used for severe and moderate cancer pain
(Caraceni et al., 2012) and also as second-line pharmacologi-
cal management of neuropathic pain (Dworkin et al., 2007).
Long-term use of opioids can, however, cause tolerance and
numerous adverse effects, including opioid-induced hyperal-
gesia, that restrict their use.
Since the first report by Trujillo and Akil (1991), the
effects of NMDA receptor antagonists have attracted great
interest in studies on opioid tolerance. Ketamine, a non-
competitive antagonist of the NMDA receptor, is highly lipo-
philic and easily crosses the blood–brain barrier (BBB) (White,
1988). Its main clinical use is as an anaesthetic agent, but it is
increasingly studied for the treatment of chronic pain and
also depression (Kavalali and Monteggia, 2012). As with
opioids, ketamine has abuse potential (Morgan et al., 2012).
At low doses, it has been shown to be efficacious in periop-
erative analgesia and in chronic pain (Bell et al., 2006; Visser
and Schug, 2006; Laskowski et al., 2011). In humans, the
elimination t1/2 of ketamine is 2–3 h and approximately 80%
of the drug undergoes hepatic metabolism to the active
metabolite norketamine after oral administration (Ebert et al.,
1997; Shimoyama et al., 1999; Sinner and Graf, 2008).
There is some evidence that ketamine coadministered
with morphine can significantly increase the efficacy of mor-
phine in cancer pain management (Bell et al., 2012). The
majority of preclinical (Trujillo and Akil, 1994; Shimoyama
et al., 1996; González et al., 1997; Miyamoto et al., 2000) and
human (Bell, 1999; Nesher et al., 2009; Arroyo-Novoa et al.,
2011; Hardy et al., 2012; Honarmand et al., 2012; Mathews
et al., 2012; Salas et al., 2012; Suppa et al., 2012) studies have
focused on the pharmacodynamic properties of ketamine as
an antagonist of the NMDA receptor leading to decreased
opioid tolerance and hyperalgesia. However, very little
information is available of any possible pharmacokinetic
interactions between opioids and ketamine. Morphine
is glucuronidated to morphine-3-glucuronide (M3G) and
morphine-6-glucuronide (M6G) by uridine diphosphate
(UDP)-glucuronosyl transferase 2B7 (UGT2B7) in humans
(Coffman et al., 1997) and mostly to M3G by UGT2b1 in
rodents (Pritchard et al., 1994; Coffman et al., 1996; King
et al., 1997). Ketamine has been shown to inhibit UGT2B7
and metabolism of morphine in vitro (Qi et al., 2010;
Uchaipichat et al., 2011). In the rat, infusion of the opioid
alfentanil has been reported to increase the distribution
volume and brain concentration of ketamine, whereas the
brain alfentanil concentration decreased during coadminis-
tration (Edwards et al., 2002). The effects of ketamine on
opioid tissue concentrations and vice versa have not been
studied during chronic treatment. Here, we studied the ability
of ketamine to restore or augment morphine antinociception
during chronic opioid treatment and tolerance, opioid with-
drawal and acute coadministration. The brain, serum and
liver morphine and ketamine concentrations were assessed at
the time point of maximum antinociception to study a pos-
sible pharmacokinetic interaction behind the phenomenon.
This study shows that ketamine coadministration to rats
under chronic morphine treatment resulted in increased
brain morphine, ketamine and norketamine concentrations
compared with rats treated with morphine or ketamine only.
This drug interaction should be considered when studying
the interactions between opioids and ketamine.
Methods
Animals
All animal care and experimental procedures were in accord-
ance with the guidelines of the International Association for
Tables of Links
TARGETS
Ligand-gated ion channela Transportersc
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Enzymesb P-gp, P-glycoprotein, ABCB1
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the Study of Pain (Zimmermann, 1983) and approved by the
provincial government of Southern Finland (Etelä-Suomen
aluehallintovirasto, Hämeenlinna, Finland, ESAVI/5684/
04.10.03/2011). Studies involving animals are reported in
accordance with the ARRIVE guidelines (Kilkenny et al., 2010;
McGrath et al., 2010). A total of 72 rats were used in the
experiments described here.
Male Sprague–Dawley rats (Scanbur, Sollentuna, Sweden;
n = 8 per group; weight, 300–350 g) were housed in groups of
four in plastic cages in standard light- and temperature-
controlled rooms (lights on at 0700 h and off at 1900 h,
temperature 22 ± 2°C). Every effort was made to minimize the
stress and suffering of the experimental animals. Tap water
and standard laboratory chow were available ad libitum.
Before the tests, the animals were habituated to the testing
environment 60 min·day–1 for 3 days. All behavioural testing
was randomized and blinded. After the experiments, the
animals were killed by decapitation and whole brain, liver
and serum samples were collected.
Drugs for acute nociceptive tests
Morphine hydrochloride and racemic ketamine hydrochlo-
ride (Ketaminol® vet, 50 mg·mL–1, Boxmeer, The Nether-
lands) were purchased from the University Pharmacy,
Helsinki, Finland. Morphine was dissolved and ketamine was
diluted in isotonic saline and administered s.c. in a volume of
2 mL·kg–1. All drug concentrations are given as free base
amounts.
Induction of morphine tolerance
Opioid tolerance was induced with continuous administra-
tion of morphine via osmotic minipumps (Alzet 2ML1,
Durect, Cupertino, CA, USA). The pumps were filled with
25 mg·mL–1 morphine in isotonic saline to deliver a constant
6 mg dose of morphine daily. In pilot experiments, this
steady dose of daily morphine induced tolerance after 5 days.
For the control animals, isotonic saline was used as a vehicle.
The pumps were implanted s.c. in the back under brief iso-
flurane (3.0%) anaesthesia. After 6 days from implantation,
the pumps were removed under similar brief anaesthesia.
Nociceptive tests
Tail flick latencies were measured with a Ugo Basile 37360
(Comerio, Italy) radiant heat tail flick device. The rats were
restrained in hard plastic tubes covered with a dark cloth. The
light was directed in turn at three different points of the
middle third of the tail. The mean of these three values was
used as the result. The intensity was adjusted to produce a
baseline latency of approximately 4 s. If an individual meas-
urement reached cut-off (10 s), no further tests were per-
formed for that particular time point.
Hot plate tests were performed with a Harvard Apparatus
Ltd. apparatus (Edenbridge, Kent, UK). The rats were kept
inside a circular transparent plastic cage on the hot plate (52
± 0.2°C). Licking or brisk shaking of the hind paw or jumping
was considered as a sign of thermal nociception. The cut-off
time was set to 60 s.
The predrug (baseline) latencies were measured separately
for each experimental day immediately before the adminis-
tration of any drugs.
Motor coordination
A rotarod apparatus (Palmer electric recording drum, United
Kingdom, diameter 80 mm, speed 12 r.p.m.) was used to
assess the effects of the test drugs on motor coordination. The
rat was placed on the rotating rod and the time the rat stayed
on it was measured. Animals that survived at least 60 s on the
rotating rod before drug administration were accepted into
the test and 60 s was also used as a cut-off time in the test
proper.
Determination of morphine, M3G, M6G,
normorphine, ketamine and norketamine
The measurements were carried out as previously described
(Zheng et al., 1998), with some modifications using an
Agilent 1100 series HPLC system (Agilent Technologies,
Waldbronn, Germany) coupled to an API 3000 tandem mass
spectrometry (AB Sciex, Toronto, Ontario, Canada) and the
chosen method was validated also for the analysis of keta-
mine and norketamine (data not shown). The chromato-
graphic separation of morphine, M3G, M6G, normorphine,
ketamine and norketamine was achieved on Atlantis HILIC
Silica column (3 μm particle size, 2.1 × 100 mm I.D.) (Waters,
Milford, MA, USA) using a gradient elution of mobile phase
consisting of acetonitrile and 20 mmol·L–1 ammonium
acetate (pH 3.0, adjusted with formic acid). An aliquot (5 μL)
was injected at a flow rate of 200 μL·min–1 to give a total
chromatographic run time of 24 min. Oxycodone served as
an internal standard for morphine and its metabolites, and
deuterium-labelled internal standards were used for ketamine
and norketamine. The target ion transitions monitored were
as follows: morphine m/z 286–152, M3G and M6G m/z 462–
286, normorphine m/z 272–152, ketamine m/z 238–125 and
norketamine m/z 224–125. The limit of quantification was
1.0 ng·mL–1 for morphine, M3G and M6G, and 0.5 ng·mL–1
for ketamine and norketamine. A signal-to-noise ratio of 20:1
was used as limit of detection for normorphine, and the
quantities were given in arbitrary units (U·mL–1) relative to
the ratio of the peak height of normorphine to that of the
internal standard. The calibration curves were linear over the
concentration range of LOQ-250 ng·mL–1, and day-to-day
coefficients of variation were below 15% at relevant concen-
trations for all analytes. None of the measured compounds
interfered with the mass spectrometric assay.
Experimental design
The experimental design is described briefly in Figure 1. We
started by investigating the effects of an acute subanaesthetic
dose of ketamine (10 mg·kg–1 s.c.) in morphine-tolerant rats
under chronic morphine treatment. On day 0, a total of 48
rats were implanted with minipumps delivering morphine
6 mg·day–1 or vehicle. On day 5, after confirming the devel-
opment of morphine tolerance with tail flick and hot plate
nociceptive tests, rats received 10 mg·kg–1 s.c. racemic keta-
mine or vehicle, and antinociception was monitored up to
210 min with tail flick and hot plate tests. The rotarod test
was used at 30 and 90 min to monitor the effect of the drugs
on motor coordination. No extra doses of morphine were
given on day 5.
As significant antinociception was noticed in the
morphine–ketamine cotreatment group, we continued the
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experiment to assess the persistence of the effects of ketamine
during the morphine withdrawal period. In the evening of
day 5, the minipumps were removed. On day 7, the rats were
administered ketamine 10 mg·kg–1 s.c. alone or in combina-
tion with 2.5 mg·kg–1 s.c. morphine. Morphine was adminis-
tered 15 min before ketamine to permit its potential effects
on ketamine pharmacokinetics.
We also assessed the acute effects of morphine and keta-
mine coadministration in drug-naïve rats. For the tissue con-
centration measurements at 90 min after acute ketamine or
vehicle administration, the rats were decapitated and whole
brain, blood and liver samples were collected. The whole
brain and part of the right lateral lobe of the liver (mean
weight 400 mg) samples were covered in aluminium foil and
snap-frozen in liquid nitrogen, after which they were stored
at −80°C. The blood samples collected in decapitation were
allowed to coagulate at room temperature for 60 min, after
which they were stirred with a glass rod and centrifuged at
4900× g for 20 min at +23°C. While on ice, serum was col-
lected and stored at −20°C.
To obtain tissue samples from day 5, a separate group of
rats (n = 24) was implanted with minipumps in a similar
fashion on day 0 and followed up to day 5. The development
of tolerance to morphine antinociception was characterized
with tail flick and hot plate tests after 1, 3 and 5 days of pump
implantation. On day 5, similar to the previously described
group of rats, acute ketamine or vehicle was administered and
samples were collected at 90 min after drug administration.
Behavioural tests were in a similar manner before the killing,
and similar behavioural results were observed as with the
previous group of animals.
Data analysis
The results of the hot plate and tail flick experiments are
expressed as percentage of the maximum possible effect
(MPE%), calculated as MPE% = [(postdrug latency – baseline
latency)/(cut-off time – baseline latency)] × 100%, which
takes into account the differences in baseline nociceptive
latencies. The results are presented as means of the groups
(±SEM). The behavioural data were tested for statistically sig-
nificant differences in the mean values by two-way ANOVA. To
detect the differences in the presence of a significant two-way
ANOVA, a Holm–Sidak post hoc analysis was performed. For the
concentration data, an unpaired two-tailed t-test or one-way
ANOVA followed by the Holm–Sidak post hoc analysis was used.
For the nonparametric rotarod test data, the Kruskal–Wallis
test followed by Dunn’s multiple comparison was used. The
difference was considered significant at P < 0.05 in both the
analysis of variance and the post hoc test. The data were
analysed using GraphPad Prism, version 6.0c for Mac OS X
(GraphPad Software, La Jolla, CA, USA).
Results
Tolerance develops after 5 days of continuous
morphine administration
Following 24 h of continuous morphine treatment, signifi-
cant antinociception was observed both in the tail flick
(Figure 2A) and hot plate (Figure 2B) tests compared with the
group that had received the vehicle. On day 5, antinocicep-
tive tolerance to morphine had developed in both tests, but
no morphine-induced hyperalgesia was observed in either of
the tests.
A low dose of ketamine induces
antinociception in opioid-tolerant rats under
chronic morphine administration but not in
morphine-naïve rats
On day 5, a low dose of ketamine or vehicle was administered
to rats under chronic minipump administration of morphine
or vehicle. Acute ketamine (10 mg·kg–1) administered to
morphine-naïve rats caused no significant antinociception
compared with vehicle only. However, ketamine adminis-
tered to morphine-tolerant rats caused significant antinocic-
Figure 1
The design of the morphine tolerance and withdrawal experiments. In experiment sets 1 (blue) and 2 (red), 48 and 24 Sprague–Dawley rats were
used respectively.
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eption compared with the morphine-naïve ketamine-treated
rats both in the tail flick (Figure 3A) and hot plate (Figure 3B)
tests. In both tests, the effect was at its peak at 90 min after
acute drug administration. In the hot plate test, a statistically
significant difference compared with the morphine-naïve
ketamine-treated group was reached already at 30 min,
whereas in the tail flick test the effect started later (90 min)
and lasted up to 150 min. Ketamine administered both to
morphine-naïve and morphine-tolerant rats decreased motor
performance in the rotarod test (Figure 3C) at 30 min when
compared with morphine-tolerant or vehicle-treated rats, but
at 90 min the motor performance had returned to normal.
Ketamine administered to morphine-tolerant rats decreased
the performance significantly more compared with the
morphine-naïve rats that were administered ketamine.
A low dose of ketamine administered to rats
under chronic morphine treatment increases
the concentration of morphine in the brain
and the liver
To study the mechanisms behind the antinociceptive effect
of ketamine in morphine-tolerant rats, we measured serum
levels and brain and liver whole-tissue concentrations of mor-
phine, M3G, ketamine and norketamine at the 90 min time
point (peak antinociception) of the previously described
experiment. No significant amounts of M6G were detected in
any sample.
In morphine-treated rats that were administered
10 mg·kg–1 s.c. ketamine, the brain concentration of mor-
phine (Figure 3D) doubled compared with the rats that were
not given acute ketamine (110% increase, P < 0.05). Mean-
while, the serum level was increased only by 10% in ketamine
coadministration (Figure 3E), indicating an increased
brain : serum ratio of morphine (0.17 ± 0.024 vs. 0.11 ± 0.018,
P < 0.05, Table 1). The M3G concentrations or levels in the
brain or serum were not significantly changed. In the liver
(Figure 3F), the morphine concentration was significantly
elevated after ketamine (120% increase, P < 0.05). However,
the liver : serum concentration ratio was not significantly
increased (Table 1). The M3G concentrations or liver : serum
concentration ratios did not significantly change. The moni-
tored normorphine peak was elevated (230% increase, P <
0.05, data not shown).
Previous chronic treatment with morphine
increases the concentrations of ketamine and
norketamine in the brain, serum and liver
Chronic morphine treatment caused a greater disposition of
ketamine into the brain compared with morphine-naïve rats
that were given ketamine (45% increase, P < 0.01, Figure 3G).
The increase of the norketamine concentration in the brain
after drug coadministration was even more pronounced
(240% increase, P < 0.001). In serum, however, ketamine and
norketamine levels were elevated as well (Figure 3H), and
thus only the brain : serum concentration ratio of norketa-
mine was significantly increased (P < 0.05, Table 1). However,
the most pronounced difference related to the morphine
pretreatment was seen in the liver ketamine concentration
(510% increase, P < 0.001, Figure 3I). The norketamine con-
centration was roughly doubled. The liver : serum concentra-
tion ratio of ketamine was increased fourfold (P < 0.001,
Table 1), but the corresponding norketamine ratio was not
altered.
The synergy in the antinociceptive effect by
morphine and ketamine cotreatment
continues in the withdrawal phase
In the evening of day 5, after the acute tests, the morphine
and vehicle pumps were removed and on day 7, the rats were
given the same dose of ketamine (10 mg·kg–1 s.c.) with or
without 2.5 mg·kg–1 s.c. morphine. In the baseline values of
nociceptive tests, no significant differences were detected
before drug administrations (data not shown). In the tail flick
Figure 2
Development of antinociceptive tolerance after morphine minipump implantations. On day 0, minipumps delivering morphine 6 mg·day–1 or
vehicle were implanted s.c. under brief isoflurane anaesthesia. The means (±SEM) of the tail flick (A) and hot plate (B) latencies are shown after
1, 3 and 5 days of pump implantation. The mean raw nociceptive latencies are presented to allow assessment of the data quality. No extra
morphine doses were given before the behavioural measurements. *P < 0.05, ***P < 0.001; significantly different from the vehicle control group;
n = 8 in the vehicle group and n = 16 in the morphine group.
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Figure 3
Effects of an acute low dose of ketamine on antinociception in morphine-tolerant rats under chronic morphine treatment. Rats under an ongoing
morphine (6 mg·day–1, Mo) or vehicle (Veh) pump treatment received an acute s.c. dose of ketamine (10 mg·kg–1, Ket) or vehicle (Veh) on day
5. Antinociception was measured using tail flick (A) and hot plate (B) tests. The mean of the maximum possible effect (MPE%) ±SEM is plotted.
In the rotarod test (C), the mean (±SEM) survival time (seconds) is plotted. From separate animals having had the same pretreatments, whole
brain, serum and liver samples were collected after 90 min of ketamine administration. The tissue concentrations and serum levels of the
experimental drugs and their main metabolites (morphine, MO; M3G; ketamine, KET; norketamine, NORKET) in the tissues were quantified and
the means of the groups (±SEM) are presented in graphs D–I. The percentage difference between the treatment groups is shown for each
compound. n = 8. **P < 0.01, ***P < 0.001; significantly different from the vehicle control group. #P < 0.05, ##P < 0.01, ###P < 0.001; significantly
different from the morphine pump treated group that received acute vehicle. §§P < 0.01, §§§P < 0.001; significantly different from the
vehicle-pretreated group that received acute ketamine.
BJP T O Lilius et al.
2804 British Journal of Pharmacology (2015) 172 2799–2813
Ta
b
le
1
Ti
ss
ue
:s
er
um
co
nc
en
tr
at
io
n
ra
tio
s
fo
r
st
ud
ie
d
dr
ug
s
on
di
ffe
re
nt
st
ud
y
da
ys
D
ay
5
(t
o
le
ra
n
ce
)
D
ay
7
(w
it
h
d
ra
w
al
)
A
cu
te
ad
m
in
is
tr
at
io
n
St
u
d
ie
d
su
b
st
an
ce
C
h
ro
n
ic
m
o
rp
h
in
e
tr
ea
tm
en
t
(d
ay
s
0
–4
)
A
cu
te
m
o
rp
h
in
e
A
cu
te
k
et
am
in
e
B
ra
in
:
se
ru
m
ra
ti
o
P
Li
ve
r
:
se
ru
m
ra
ti
o
P
B
ra
in
:
se
ru
m
ra
ti
o
P
Li
ve
r
:
se
ru
m
ra
ti
o
p
B
ra
in
:
se
ru
m
ra
ti
o
P
Li
ve
r
:
se
ru
m
ra
ti
o
P
M
o
rp
h
in
e
+
–
–
0.
11
±
0.
01
8
*
1.
9
±
0.
38
n.
s.
–
–
–
–
+
–
+
0.
17
±
0.
02
4
2.
8
±
0.
36
+
+
–
–
–
1.
2
±
0.
11
n.
s.
2.
9
±
0.
53
n.
s.
+
+
+
0.
99
±
0.
09
1
2.
8
±
0.
23
–
+
–
–
–
0.
87
±
0.
13
n.
s.
1.
3
±
0.
13
*
–
+
+
0.
95
±
0.
09
1
1.
9
±
0.
22
K
et
am
in
e
–
–
+
2.
9
±
0.
09
0
n.
s.
3.
0
±
0.
66
**
*
4.
0
±
0.
47
n.
s.
4.
7
±
1.
5
n.
s.
4.
0
±
0.
47
n.
s.
4.
7
±
1.
5
n.
s.
+
–
+
2.
7
±
0.
18
13
±
2.
1
3.
9
±
0.
10
6.
2
±
0.
69
–
–
+
+
+
–
–
4.
3
±
0.
23
5.
3
±
0.
58
–
+
+
–
–
3.
7
±
0.
21
5.
2
±
1.
4
N
o
rk
et
am
in
e
–
–
+
0.
85
±
0.
04
2
*
15
±
1.
2
n.
s.
0.
99
±
0.
15
n.
s.
19
±
3.
9
n.
s.
0.
99
±
0.
15
n.
s.
19
±
3.
9
n.
s.
+
–
+
1.
0
±
0.
05
9
12
±
1.
1
1.
2
±
0.
08
3
15
±
1.
3
–
–
+
+
+
–
–
1.
17
±
0.
08
0
15
±
0.
90
–
+
+
–
–
1.
0
±
0.
77
16
±
1.
7
Ti
ss
ue
:s
er
um
(b
ra
in
:s
er
um
an
d
liv
er
:s
er
um
)
ra
tio
s
(m
ea
n
±
SE
M
,n
=
8)
fo
r
m
or
p
hi
ne
,k
et
am
in
e
an
d
no
rk
et
am
in
e
sh
ow
n
fo
r
di
ffe
re
nt
ex
p
er
im
en
t
da
ys
.*
,*
**
P
<
0.
05
an
d
P
<
0.
00
1,
re
sp
ec
tiv
el
y,
be
tw
ee
n
th
e
tw
o
gr
ou
p
s.
n.
s.
,
no
n-
si
gn
ifi
ca
nt
.
BJPKetamine alters morphine brain access in tolerance
British Journal of Pharmacology (2015) 172 2799–2813 2805
test (Figure 4A), acute ketamine did not cause any antinoci-
ception in the morphine-naïve or rats under morphine
withdrawal. Morphine 2.5 mg·kg–1 s.c. given to rats under
morphine withdrawal caused only minor antinociception at
30 min compared with vehicle (14 ± 6.6% MPE), whereas a
statistically significantly greater response was measured in
drug-naïve animals (71 ± 13%MPE, data shown in Figure 5A),
indicating that the morphine tolerance had persisted. During
morphine withdrawal, when ketamine was coadministered
with morphine, significantly greater antinociception was
achieved compared when morphine was administered alone
(28 ± 9.1% MPE, P < 0.01) at 30 min but no more at 90 min.
In the hot plate test (Figure 4B), statistically significant but
minor antinociception was observed at 30 min in three
groups (morphine-tolerant rats that were acutely adminis-
tered morphine, ketamine, or both) compared with vehicle
but no more at 90 min. In the rotarod test (Figure 4C), motor
impairment was noticed in the morphine withdrawal group
that was acutely treated with both morphine and ketamine
(38 ± 11 s, P < 0.05 compared with ketamine only).
The increased accumulation of ketamine
continues in rats under morphine withdrawal
Two days after the removal of morphine minipumps, the
measured morphine serum levels and brain and liver concen-
trations were 2.2 ± 0.65 ng·mL–1, 0.31 ± 0.31 ng·g–1 and 34 ±
8.3 ng·g–1 respectively (n = 8). The corresponding M3G con-
centrations were 7.8 ± 3.0 ng·mL–1, 0.38 ± 0.27 ng·g–1 and 13
± 4.8 ng·g–1, indicating almost complete washout of the sub-
stances. As noticed during chronic morphine administration,
the coadministration of ketamine with morphine increased
the concentration of morphine in the brain (39% increase,
P < 0.05, Figure 4D) also during withdrawal. A significant
increase of morphine was observed also in the serum (71%
increase, P < 0.001, Figure 4E) and liver (58% increase, P <
0.05, Figure 4F). The tissue : serum concentration ratios of
morphine did not significantly differ between groups
(Table 1).
The effect of morphine on ketamine concentrations
during withdrawal was assessed in three groups. The first
(control) morphine-naïve group received ketamine only. The
two groups under morphine withdrawal received ketamine
with or without acute morphine. Previous morphine pump
treatment increased the brain norketamine concentration
(99% increase, P < 0.001, Figure 4G) but not the ketamine
concentration. Norketamine levels were significantly greater
in the serum as well (Figure 4H). The coadministration of
acute morphine did not significantly alter the increase. In the
liver, an increase in the ketamine concentration (110%, P <
0.05) was observed in the withdrawal group that was admin-
istered ketamine only (Figure 4I). When acute morphine was
combined to ketamine, no significant difference was found.
During withdrawal, no morphine-induced alterations in the
tissue : serum concentration ratios of ketamine and norketa-
mine were detected (Table 1).
Acute coadministration of morphine and
ketamine increases the brain and liver
morphine concentrations in naïve animals
Finally, we assessed the effects of acute morphine and keta-
mine coadministration in morphine-naïve rats previously
treated with vehicle pumps. The experiment was performed
concomitantly with the withdrawal experiment to allow sta-
tistical comparisons. Morphine (2.5 mg·kg–1, s.c.) was admin-
istered 15 min before ketamine (10 mg·kg–1, s.c.).
In the tail flick test (Figure 5A), ketamine or vehicle
administrations alone did not cause any antinociception.
Compared with vehicle, morphine alone caused significant
antinociception at 30 and 90 min. When ketamine was coad-
ministered with morphine, no changes in antinociception
were observed when compared with the morphine only
group.
In the hot plate test (Figure 5B), no antinociception by
ketamine was observed. Morphine alone caused minor anti-
nociception at 30 min (19 ± 5.3% MPE, P < 0.05 compared
with vehicle). Ketamine coadministration had an additive
effect at 30 min (39 ± 5.7% MPE, P < 0.05 compared with
morphine only). In the rotarod test (Figure 5C), morphine or
ketamine alone caused no motor impairment, but the com-
bination of morphine and ketamine significantly impaired it
at 30 min (31 ± 9.4 s, P < 0.05 compared with ketamine only).
In the brain (Figure 5D), a 23% increase (P < 0.05) of the
morphine concentration was observed in the morphine- and
ketamine-cotreated rats when compared with the morphine-
treated group. In the serum (Figure 5E), no significant
changes were observed, but in the liver morphine concentra-
tion was significantly elevated after coadministration. An
increased liver : serum concentration ratio of morphine
(P < 0.05, Table 1) was observed, whereas the increase in
brain : serum concentration ratio was not significant. Mor-
phine coadministration did not cause any significant changes
in the ketamine or norketamine concentrations (Figures
5G–I) or tissue : serum concentration ratios (Table 1).
Metabolic ratios of the studied drugs in
chronic administration of morphine,
morphine withdrawal and
acute coadministration
The metabolic ratios (M3G : morphine and norketamine :
ketamine) on different study days in serum and liver are
presented in Table 2. Acute ketamine treatment significantly
decreased the M3G : morphine metabolic ratio in the liver,
but not in serum, on all experimental days. Acute coadmin-
istration of morphine did not have an effect on the metabolic
ratio of ketamine. However, chronic morphine treatment
induced an increase in the serum norketamine : ketamine
metabolic ratio on day 5 and a significant decrease in the liver
on days 5 and 7.
Discussion
The main finding of the study was that a single small dose of
ketamine caused long-lasting antinociception in rats under
chronic morphine treatment, whereas administration to
naïve animals had no antinociceptive effect. The time point
of maximum antinociception cotreatment caused a large
increase in the brain concentrations of morphine, ketamine
and norketamine, suggesting that morphine and ketamine
may have pharmacokinetic interactions in addition to the
previously reported pharmacodynamic interactions during
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Figure 4
Effects of an acute low dose of ketamine, morphine and their combination on antinociception in morphine-tolerant rats under morphine
withdrawal. Rats had morphine pumps that delivered morphine (Mo) or vehicle (Veh) 6 mg·day–1 for 5 days in total. On the evening of day 5,
the morphine pumps were removed. On day 7, rats in morphine withdrawal received s.c. doses of morphine, ketamine or a combination. Control
animals received vehicle or ketamine. Morphine was administered 15 min before ketamine. Antinociception was measured using tail flick (A) and
hot plate (B) tests. The mean of the maximum possible effect (MPE%) ±SEM is plotted. In the rotarod test (C), the mean (±SEM) survival time
(seconds) is plotted. Whole brain, serum and liver samples were collected after 90 min of ketamine administration. The tissue concentrations and
serum levels of the experimental drugs and their main metabolites (morphine, MO; M3G; ketamine, KET; norketamine, NORKET) in the tissues
were quantified and the means of the groups (±SEM) are presented in graphs D–I. The percentage difference between the treatment groups is
shown for each compound. n = 8. *P < 0.05, **P < 0.01, ***P < 0.001; significantly different from the vehicle control group. #P < 0.05,
###P < 0.001; significantly different from the morphine pump treated group that received acute morphine only. §P < 0.05, §§P < 0.01, §§§P <
0.001; significantly different from the vehicle-pretreated group that received acute ketamine.
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Figure 5
Effects of an acute low dose of ketamine on antinociception in acute coadministration with morphine. Rats received an acute s.c. dose of ketamine
(10 mg·kg–1, Ket) or vehicle (Veh). Morphine was given 15 min before ketamine. Antinociception was measured using tail flick (A) and hot plate
(B) tests. The mean of the maximum possible effect (MPE%) ±SEM is plotted. In the rotarod test (C), the mean (±SEM) survival time (seconds)
is plotted. Whole brain, serum and liver samples were collected after 90 min of ketamine administration. The tissue concentrations and serum
levels of the experimental drugs and their main metabolites (morphine, MO; M3G; ketamine, KET; norketamine, NORKET) in the tissues were
quantified and the means of the groups (±SEM) are presented in graphs D–I. The percentage difference between the treatment groups is shown
for each compound. n = 8, except n = 7 in the morphine-treated group. *P < 0.05, **P < 0.01, ***P < 0.001; significantly different from the vehicle
control group. #P < 0.05, ##P < 0.01, ###P < 0.001; significantly different from morphine only. §P < 0.05, §§§P < 0.001; significantly different
from acute ketamine only.
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chronic morphine treatment. Chronic morphine administra-
tion apparently decreased elimination of ketamine, as it
radically increased the concentrations of ketamine and nor-
ketamine in the brain, serum and liver during the elimination
phase. During morphine withdrawal, the synergistic antino-
ciceptive effect of ketamine and morphine in coadministra-
tion was still present but to a smaller extent as was the
accumulation of morphine and norketamine to the brain.
Acute morphine and ketamine cotreatment in naïve rats did
not have such effects, suggesting that chronic morphine
treatment may modify the expression of proteins affecting
ketamine pharmacokinetics.
Possible connection between increased
antinociception and increased drug brain
concentrations during morphine tolerance
A summary of the changes in the brain drug concentrations
is shown in Table 3. The most prominent cotreatment-
induced increases in morphine, ketamine and norketamine
brain concentrations were observed during chronic mor-
phine administration, during which the increase of antino-
ciception was also remarkable in the morphine-tolerant rats.
The brain concentration of morphine was increased by 110%,
and those of ketamine and norketamine by 40 and 240%
respectively.
It is important to note that brain morphine concentra-
tions 90 min after acute ketamine treatment on day 7 were
higher (Figure 4D, measurement was made 105 min after
acute s.c. morphine treatment during the elimination phase)
compared with day 5 (Figure 3D, the morphine concentra-
tions were at steady state as a result of the 5 day pump
treatment before acute ketamine that increased morphine
concentrations by 110%). In spite of this, acute ketamine
combined with morphine did not cause antinociception
(1.4%MPE, Figure 4A) on day 7 but caused a time-dependent,
maximal 57% MPE (Figure 3A) increase in the tail flick
latency on day 5. Therefore, surprisingly, acute ketamine
treatment did not restore morphine antinociception at
90 min in morphine-tolerant rats on day 7 as it did on day 5.
This result suggests that a pharmacodynamic interaction
alone does not explain the higher potency of ketamine
during morphine tolerance. In addition, the considerably
increased antinociception in morphine-tolerant, ketamine-
treated rats may not be solely due to the increased brain
concentrations of morphine or ketamine because their con-
centrations were at the same level on days 5 and 7. However,
a notable (doubled) increase in the brain norketamine con-
centration was observed. Thus, the increased brain norketa-
mine concentration may be an important factor contributing
to the increased antinociception on day 5.
At the peak antinociception on day 5, the brain molar
concentration of norketamine exceeded that of ketamine by
110%, supporting the idea that the increase is significant. In
binding studies, norketamine has been identified as a potent
NMDA receptor antagonist: Ebert et al. (1997) reported that
S-norketamine is approximately five times weaker than
S-ketamine. In rats, norketamine has been shown to have
antinociceptive properties (Shimoyama et al., 1999; Holtman
et al., 2008a) and it potentiated morphine antinociception
in thermal nociception, peripheral neuropathy and tonic
inflammatory pain models (Holtman et al., 2008b). InTa
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humans, the peak analgesic effect after oral ketamine admin-
istration occurred at the peak plasma norketamine, not keta-
mine, concentration (Grant et al., 1981). Taken together, our
results showed that a single low dose of ketamine, given
during opioid tolerance, induced important brain drug con-
centration changes that may have a role in augmenting
the pharmacodynamic effects of ketamine in morphine
tolerance.
Effects of ketamine administration on
morphine pharmacokinetics
After ketamine administration to rats under chronic mor-
phine treatment, the brain concentration of morphine was
doubled at maximum antinociception (Figure 3D) and the
brain : serum concentration ratio was increased (Table 1)
implicating increased disposition of morphine in the CNS. A
similar, although smaller, effect was seen under morphine
withdrawal (39% increase, Figure 4D) and in acute coadmin-
istration (23% increase, Figure 5D). In these situations,
however, the brain : serum concentration ratios were not sig-
nificantly increased. Morphine is a substrate for the trans-
porters, P-glycoprotein (P-gp) and the multidrug resistance
protein (MRP), both of which are efflux proteins at the BBB
(Schinkel et al., 1995; Letrent et al., 1999; Xie et al., 1999; Su
and Pasternak, 2013). The inhibition of such efflux proteins
by ketamine could account for decreased efflux and concomi-
tantly increased disposition of morphine in the brain.
However, there no published reports of ketamine as an
inhibitor or substrate of P-gp (Doan, 2002; Varma et al., 2005)
or MRP. Morphine may also be a substrate of the rat organic
cation transporter proteins (Amphoux et al., 2006), influx
proteins at the BBB. Inhibition of these proteins by ketamine
(Tzvetkov et al., 2013) would lead to decreased CNS mor-
phine concentrations, contrary to the changes observed.
Thus, the mechanism behind the increased brain : serum
concentration ratio of morphine on day 5 remains unclear.
Ketamine increased morphine concentrations in the liver
in all experiments (Figures 3C, 4C and 5C) and decreased
the M3G : morphine metabolic ratio (Table 2), indicating
decreased hepatic metabolism of morphine to its glucuronide
M3G. Previous in vitro studies (Qi et al., 2010; Uchaipichat
et al., 2011) have shown that ketamine may inhibit the
metabolism of morphine by UGT enzymes and our present in
vivo results support this finding. However, decreased hepatic
metabolism of morphine leads to increased serum morphine
concentrations only on day 7 whereas serumM3G levels were
not decreased in any experiment. Thus, the inhibition of
efflux proteins rather than decreased metabolism might
explain the increased brain concentration of morphine after
ketamine treatment.
Effects of chronic morphine treatment on
ketamine and norketamine distribution
Interestingly, acute coadministration of ketamine during
chronic morphine treatment caused a large accumulation of
ketamine and norketamine in liver, serum and brain (Figure
3G–I). Moreover, this effect persisted, even though to a lesser
extent, during the withdrawal period and it was independent
of an acute dose of morphine (Figure 4G–I). Similar accumu-
lation could not be seen after acute coadministration in
morphine-naïve animals (Figure 5G–I), strongly suggesting
chronic morphine treatment-induced changes in the func-
tion of metabolic enzymes or transporter proteins affecting
ketamine pharmacokinetics. At high (overdose) concentra-
tions, ketamine is metabolized to norketamine mainly by
cytochrome P (CYP)3A4, but at lower therapeutic concentra-
tions also CYP2B6 has a profound role in the metabolism
(Hijazi, 2002; Li et al., 2013). Importantly, however, also the
norketamine concentrations were increased during coadmin-
istration. This result indicates that CYP enzyme inhibition is
not the key factor explaining ketamine accumulation.
One possible explanation of the morphine tolerance-
induced ketamine accumulation would be the down-
regulation of a ketamine (or its metabolite) efflux transporter
or the up-regulation of a reuptake transporter. The effects of
chronic morphine treatment on the induction of xenobiotic
receptors, transporters and drug-metabolizing enzymes is
not thoroughly known, but chronic oxycodone has been
reported to significantly down- or up-regulate 27 different
drug transporters in the rat liver (Hassan et al., 2013).
Table 3
A summary of the changes of the mean brain drug concentrations (%) and tail flick latencies (MPE%) during coadministration of morphine and
ketamine compared with the groups that received only morphine or ketamine
Variable
Tolerance
(day 5) P
Withdrawal with
acute morphine
(day 7) P
Withdrawal without
acute morphine
(day 7) P
Acute
coadm P
Morphine concentration +110 * +39 * n/a n/a +23 *
Ketamine concentration +45 ** +32 n.s. +28 n.s. –9 n.s.
Norketamine
concentration
+240
***
+71
**
+99
***
+15
n.s.
Tail-flick latency +54 *** +13 * 0 n.s. +9 n.s.
The maximal change of the tail flick response in percentage units is shown for each experiment (morphine and ketamine-cotreated group vs.
the groups that received only morphine or ketamine). For the exact treatment schemes of every experiment, please see the Methods section.
*, **, ***P < 0.05, P < 0.01, P < 0.005 respectively. Coadm, coadministration; n.s., nonsignificant; n/a, not available (no morphine was
administered to these rats).
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However, in the light of current knowledge about transporter
proteins for ketamine, the demonstrated change in ketamine
pharmacokinetics during chronic morphine treatment
remains unexplained. Of clinical interest, the accumulation
of ketamine during chronic morphine administration could
potentially increase the risk for hepatic toxicity (Bell, 2012).
Effects on the BBB
Acute lipopolysaccharide treatment has been reported to
lower plasma ketamine AUC and increase its elimination t1/2,
indicating increased BBB permeability and access of ketamine
into the brain (Vachon et al., 2012). In repeated administra-
tion, morphine may also increase the permeability of the BBB
(Sharma and Ali, 2006). This provides another interesting
theory for the altered pharmacokinetics of ketamine in mor-
phine tolerance.
Conclusion
The results of the present study indicate a novel pharmacoki-
netic mechanism behind the interaction between chronic
morphine administration and ketamine. The coadministra-
tion resulted in greatly increased concentrations of both
parent drugs and also norketamine in the CNS. The results
also suggest a probable decrease in the elimination of keta-
mine, as the concentrations of ketamine and its main
metabolite norketamine were increased in all observed tissues
at the elimination phase. This phenomenon was observed
also during the morphine withdrawal period. Based on these
results, it is difficult to define the exact contribution of the
pharmacokinetic interaction to the increased antinocicep-
tion. However, these results may help in explaining the
profound ketamine analgesia often observed in morphine-
tolerant patients. More research is needed to clarify the
mechanisms of morphine-induced changes in ketamine
pharmacokinetics. These findings also imply that possible
changes in ketamine and morphine brain concentrations
should be taken into account in future studies that involve
coadministration of these drugs.
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